Lead Product(s) : Trontinemab
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Patient Death Prompts Roche to Adjust Alzheimer's Trial
Details : RG6102 (trontinemab) is a novel Brainshuttle Aβ antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with AD.
Product Name : RG6102
Product Type : Antibody
Upfront Cash : Inapplicable
October 30, 2024
Lead Product(s) : Trontinemab
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $509.0 million
Deal Type : Licensing Agreement
AC Immune Receives Second Milestone Payment For Progress in ACI-35.030 Phase 2b
Details : Through the license agreement, AC Immune is investigating active immunotherapy candidate JNJ-2056 (ACI-35.030) to treat patients suffering from preclinical (pre-symptomatic) Alzheimer’s disease.
Product Name : ACI-35.030
Product Type : Vaccine
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $509.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
AC Immune’s ACI-35.030 Granted FDA Fast Track Designation for Alzheimer’s Disease
Details : ACI-35.030 (JNJ-2056) is designed to enhance the formation of broad-spectrum protective antibodies against pTau being developed for Alzheimer’s Disease.
Product Name : ACI-35.030
Product Type : Vaccine
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-24.060
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $2,200.0 million
Deal Type : Licensing Agreement
AC Immune and Takeda Sign Agreement for Alzheimer's Immunotherapy Targeting Amyloid Beta
Details : Under the agreement, Takeda will receive exclusive option to license global rights to ACI-24.060, a potential first-in-class, anti-Abeta active immunotherapy for Alzheimer’s disease.
Product Name : ACI-24.060
Product Type : Vaccine
Upfront Cash : $100.0 million
May 13, 2024
Lead Product(s) : ACI-24.060
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $2,200.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACI-35.030 previously named as JNJ-64042056 is the first-in-class anti-pTau vaccine candidate which is being evaluated in phase 1/2 clinical trials for the treatment of Alzheimer’s Disease.
Product Name : ACI-35.030
Product Type : Vaccine
Upfront Cash : Inapplicable
December 15, 2023
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-24.060
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.
Product Name : ACI-24.060
Product Type : Vaccine
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : ACI-24.060
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-24.060
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, and thereby may reduce or prevent disease progression.
Product Name : ACI-24.060
Product Type : Vaccine
Upfront Cash : Inapplicable
January 26, 2023
Lead Product(s) : ACI-24.060
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
Details : Early clinical testing showed that ACI-35.030, a first-in-class anti-pTau vaccine, was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and ePHF species, both of which are close...
Product Name : ACI-35.030
Product Type : Vaccine
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030, a first-in-class tau vaccine candidate in participants with early Alzheimer’s disease treatment.
Product Name : ACI-35.030
Product Type : Vaccine
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
Details : Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease.
Product Name : ACI-35.030
Product Type : Vaccine
Upfront Cash : Inapplicable
November 02, 2021
Lead Product(s) : ACI-35.030
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable